Sign in
Not yet taking people in United StatesNo phase

Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia

Key facts

Who runs it
National Heart, Lung, and Blood Institute (NHLBI)
Where
Bethesda, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
48 people, planned
Starts
23 Nov 2026
Expected to end
31 Mar 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High fat liquid shake
Record updated
18 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (35)Hide the full registry criteria

Who cannot take part

  • Subjects with anticipated surgery during the study period
  • Subjects with severe medication-resistant claustrophobia
  • Subjects who are unwilling to stop medications, vitamins, and/or dietary supplements that investigators have requested to be held
  • Subjects with type 1 diabetes
  • Subjects with a history of pancreatitis, diabetes ketoacidosis, hyperosmolar hyperglycemic state, advanced atherosclerosis, cardiovascular diseases, kidney diseases, or liver diseases
  • Subjects with fat malabsorption, including a history of gastrointestinal surgery, pancreatic insufficiency, inflammatory bowel disease, celiac disease, moderate-to-severe irritable bowel syndrome, or pathologic mutations impacting lipoprotein metabolism
  • Subjects with HIV
  • Subjects with uncontrolled psychiatric and/or behavioral disorders
  • Subjects taking diabetes medications other than metformin
  • Any other reason or clinical condition that the investigators judge would interfere with study participation and/or be unsafe for the participant or staff member
  • Subjects older than 65 years. This age group has significantly increased risk of cardiovascular diseases. To minimize the risk from temporarily suspending lipid- and glucose-lowering medications and the stress from serial blood draws, these individuals are excluded
  • Subjects with hemoglobin <11 g/dL or hematocrit <33%
  • Subjects younger than 18 years old. This age group has a broad spectrum of hormonal profiles due to development and puberty, which significantly increases the heterogenicity of study subjects
  • Women who are pregnant or currently breastfeeding
  • Heavy alcohol use within past 12 months (males: >2 drinks per day or >14 drinks per week; females: >1 drink per day or >7 drinks per week)
  • Current smoker, or former smoker who quit smoking less than 15 years ago
  • Subjects with weight changes greater than 20% of baseline body weight (self-reported or documented within past 12 months) over the past 3 months at outpatient visit 1, or change from outpatient visit 1 during screening
  • Subjects with lactose intolerance who are unwilling to take lactase
  • Subjects with clinically significant abnormal liver function test results
  • Subjects with liver fat >= 2% on abdominal MRI
  • Subjects on glucocorticoids for more than 1 week (not including topical glucocorticoids) within past 3 months
  • Subjects participating in any other clinical study without informing investigators

Other criteria

  • INCLUSION CRITERIA:; Cohort 1
  • Males and females aged 18 to 65 years
  • BMI 18.5 26.9 kg/m\^2
  • Able to understand the study procedures and provide written consent, and willing to comply with all scheduled follow-up visits and assessments
  • Normotensive and not on antihypertensive medications, blood pressure 90-129/60-84
  • Not on glucose-lowering or lipid-lowering medications
  • At screening, laboratory values meet all of the following:; HbA1c < 5.7%,; Fasting triglycerides < 150 mg/dL; LDL < 100 mg/dL; Liver fat < 2%; Cohort 2
  • Males and females aged 18 to 65 years
  • BMI > 26.0 to < 36.0 kg/m2
  • Able to understand the study procedures and provide written informed consent, and willing to comply with all scheduled follow-up visits and assessments
  • At screening, laboratory values meet all of the following:; HbA1c <= 7.5%; Fasting triglycerides < 500 mg/dL; LDL < 190 mg/dL
  • Willing to discontinue oral glucose-lowering medications (metformin) and oral lipidlowering medications for 4 to 10 weeks prior to the inpatient visit, if applicable
  • Liver fat < 2%

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Lipid metabolism disorders

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Robert Shamburek, M.D.Not yet recruiting

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Obesity is known to lead to diseases such as diabetes and high cholesterol (or fats) in the blood (hyperlipidemia). But no one knows why. Researchers think that high levels of fat in the blood may block important nutrients, such as vitamin E, from reaching places they are needed in the body.

Objective:

To learn how high-fat meals affect levels of vitamin E in the blood.

Eligibility:

People aged 18 to 65 with high blood fat levels. Healthy volunteers are also needed.

Design:

Participants will have 3 or 4 clinic visits in 3 months. The last visit will require them to stay in the clinic for 2 nights.

Participants will be screened. They will have a physical exam and blood tests.

After this visit, all participants must stop taking any dietary supplements.

Those who use them must also stop taking any drugs to lower their blood sugar and blood fats. These participants will have an extra visit for blood tests after 60 days.

The next visit will include 2 imaging scans:

Magnetic resonance imaging (MRI) of the abdomen. This scan will check for fat in the liver.

Dual-energy X-ray absorptiometry (DEXA). This scan measures the levels of body fat.

On day 1 of the clinic stay, participants will have 2 set meals, with nothing but water after 10 pm.

On day 2, they will drink high-fat shakes at 9am, 1pm, and 5pm. They will have blood draws every 30 minutes for the first hour, every hour the next 16 hours, and then every 2 hours until 7 am. The blood will be taken from a tube inserted into a vein and left in place for the day.

On day 3, they will go home.

The 2 groups in the trial

  • Healthy subjectsExisting treatment, for comparison

    Three consecutive high-fat vitamin E-stripped meals

    Treatment: High fat liquid shake

  • Subjects with hyperlipidemiaTreatment being tested

    Three consecutive high-fat vitamin E-stripped meals

    Treatment: High fat liquid shake

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Plasma Lipids-dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Criteria questions
Built from NCT07715890, who can take part
Record updated
18 November 2026